Kymera Therapeutics KYMR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's accrued expenses?
- Kymera Therapeutics (KYMR) reported accrued expenses of $976K in Q1 2026.
- How has Kymera Therapeutics's accrued expenses changed year-over-year?
- Kymera Therapeutics's accrued expenses increased by 9.3% year-over-year, from $893K to $976K.
- What is the long-term trend for Kymera Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Kymera Therapeutics's accrued expenses has grown at a 18.0% compound annual growth rate (CAGR), from $106K to $242K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.